Q2 EPS Estimates for Biogen Reduced by Needham & Company LLC

Biogen Inc. (NASDAQ:BIIB) – Analysts at Needham & Company LLC reduced their Q2 2026 EPS estimates for Biogen in a research report issued to clients and investors on Thursday, April 30th. Needham & Company LLC analyst A. Fadia now anticipates that the biotechnology company will post earnings per share of $2.90 for the quarter, down from their prior forecast of $4.40. The consensus estimate for Biogen’s current full-year earnings is $14.21 per share. Needham & Company LLC also issued estimates for Biogen’s Q3 2026 earnings at $4.28 EPS, Q4 2026 earnings at $3.84 EPS, FY2026 earnings at $14.58 EPS, FY2027 earnings at $16.25 EPS, FY2028 earnings at $17.85 EPS, FY2029 earnings at $18.20 EPS and FY2030 earnings at $18.95 EPS.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, beating analysts’ consensus estimates of $2.95 by $0.62. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The business had revenue of $2.48 billion for the quarter, compared to analysts’ expectations of $2.29 billion. During the same period last year, the business earned $3.02 earnings per share. The business’s quarterly revenue was up 1.9% on a year-over-year basis. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS.

Other research analysts have also recently issued reports about the stock. Canaccord Genuity Group increased their price target on shares of Biogen from $230.00 to $245.00 and gave the company a “buy” rating in a research report on Wednesday, April 1st. Barclays started coverage on shares of Biogen in a report on Thursday, February 19th. They issued an “equal weight” rating and a $185.00 target price on the stock. HSBC raised their target price on shares of Biogen from $143.00 to $150.00 and gave the stock a “reduce” rating in a report on Tuesday, March 17th. Morgan Stanley raised their target price on shares of Biogen from $200.00 to $206.00 and gave the stock an “equal weight” rating in a report on Thursday, April 30th. Finally, Stifel Nicolaus raised their target price on shares of Biogen from $202.00 to $214.00 and gave the stock a “buy” rating in a report on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $214.23.

Biogen Stock Up 0.8%

Shares of NASDAQ BIIB opened at $190.68 on Thursday. Biogen has a one year low of $115.25 and a one year high of $202.41. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.41. The firm’s 50 day simple moving average is $184.35 and its two-hundred day simple moving average is $177.16. The stock has a market capitalization of $28.15 billion, a P/E ratio of 20.46, a PEG ratio of 1.66 and a beta of 0.19.

Insider Buying and Selling

In related news, insider Priya Singhal sold 2,660 shares of the firm’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the completion of the sale, the insider owned 8,043 shares of the company’s stock, valued at $1,607,232.69. This trade represents a 24.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.18% of the stock is owned by insiders.

Hedge Funds Weigh In On Biogen

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Reflection Asset Management purchased a new position in Biogen during the fourth quarter valued at $25,000. WPG Advisers LLC lifted its position in Biogen by 417.9% during the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 117 shares during the period. Accredited Wealth Management LLC lifted its position in Biogen by 1,233.3% during the third quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 185 shares during the period. First Horizon Corp purchased a new position in Biogen during the fourth quarter valued at $30,000. Finally, WFA of San Diego LLC purchased a new position in Biogen during the second quarter valued at $32,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.